$QTRX News

TD Cowen Maintains Hold on Quanterix, Raises Price Target to $3.5

/C O R R E C T I O N -- ALZpath, Inc./

ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Quanterix, Innovita Biological Technology Receives Regulatory Nods From China For Quanterix SIMOA Technology, Neurology Biomarker Testing

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Canaccord Genuity Maintains Hold on Quanterix, Lowers Price Target to $3

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher

Quanterix: The Market Was Right To Lose Patience (Rating Downgrade)

TD Cowen Maintains Hold on Quanterix, Lowers Price Target to $3

Quanterix Corporation 2026 Q2 - Results - Earnings Call Presentation

Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even

Quanterix Q2 Earnings Call Highlights

Quanterix Names Jim Gute Chief Commercial Officer